Core Insights - MIRA Pharmaceuticals has strengthened its pipeline with the acquisition of SKNY Pharmaceuticals, focusing on a differentiated oral candidate, SKNY-1, which has shown up to 30% weight loss and reversal of nicotine cravings in preclinical studies [1] Company Developments - MIRA Pharmaceuticals, a clinical-stage pharmaceutical company, specializes in developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders [1] - The acquisition of SKNY Pharmaceuticals was approved by MIRA's stockholders during the 2025 Annual Meeting [1]